Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
ISSN: 2155-9880
Felix Nunura
Heart Institute of the Caribbean, Kingston,
Jamaica
Research Article
Real-World Evidence for the Tolerance and Effectiveness of the First Drug (Sacubitril/Valsartan) in a New Class-ARN in Afro-Caribbean Patients with Heart Failure with Reduced Ejection Fraction
Author(s): Felix Nunura, Edwin Tulloch-Reid, Daniel Nepaul, Dainia S Baugh and Ernest C MaduFelix Nunura, Edwin Tulloch-Reid, Daniel Nepaul, Dainia S Baugh and Ernest C Madu
Background: The guidelines have recommended Sacubitril/Valsartan as a substitute to Angiotensin Converting Enzyme Inhibitors (ACEIs), to further reduce the risk of hospitalization and death in ambulatory patients with Heart Failure with reduced Ejection Fraction (HFrEF). However, extensive real-world evidence for its tolerance, safety and efficacy in Blacks, has been lacking. We present additional data on real world about the use of Sacubitril/Valsartan in the unique Afro-Caribbean population with HFrEF.Methods: A cohort of 44 patients (Age 58 ± 1.91 years-old, 61.36% Male, Hypertensive 72.7, Diabetic 25%, Ischemic Cardiomyopathy 47.7)) with HFrEF (LVEF: 27.37 ± 1.19) seen at the Heart Institute of the Caribbean in Jamaica between August 2017 and September 2018 was examined. Clinical Data, heart failure features and the frequency of Prospectively Identified Adverse Eve.. View More»